Kristi Midgarden, MD
Family Medicine · Park River, NDNPI 1841374030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amgen at 29.7% of the total. Among family medicine clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$873
- AbbVie$503
- Novo Nordisk$265
- Astellas Pharma US Inc$245
- Merck$132
- Lilly USA, LLC$105
- plus $813 from 24 others
What the payments were for
- Food & beverage$2,84197%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 52 | $873 |
| AbbVie(2 entities) | 32 | $503 |
| Novo Nordisk | 18 | $265 |
| Astellas Pharma US Inc | 11 | $245 |
| Merck | 7 | $132 |
| Lilly USA, LLC | 7 | $105 |
| Pfizer | 7 | $105 |
| Sanofi-aventis U.S. LLC | 6 | $91 |
| Mylan Specialty L.p. | 5 | $76 |
| AstraZeneca | 4 | $59 |
| Bayer | 3 | $52 |
| Novartis | 3 | $51 |
| Lundbeck LLC | 3 | $49 |
| Boehringer Ingelheim | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Myriad Women's Health, Inc. | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Organogenesis Inc. | 1 | $21 |
| Smith+Nephew | 1 | $18 |
| Cepheid | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Incyte Corporation | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
How this compares
$2,935 in reported general payments places this provider in the 90th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 144 | $99,144 |
| OzempicSemaglutide | 45 | $53,892 |
| RybelsusSemaglutide | 20 | $48,500 |
| JanuviaSitagliptin Phosphate | 76 | $36,914 |
| XareltoRivaroxaban | 39 | $31,089 |
| MyrbetriqMirabegron | 50 | $28,643 |
| JardianceEmpagliflozin | 29 | $21,114 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 70 | $16,260 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $12,299 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $10,357 |
| FarxigaDapagliflozin Propanediol | 13 | $7,749 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 22 | $7,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $7,079 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $6,910 |
| Levothyroxine Sodium | 522 | $6,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $105 | $104,591162 claims |
| Novo NordiskOzempic, Rybelsus | $265 | $102,39265 claims |
| MerckJanuvia | $132 | $36,91476 claims |
| Johnson & JohnsonXarelto | $15 | $31,08939 claims |
| Astellas Pharma US IncMyrbetriq | $245 | $28,64350 claims |
| Boehringer IngelheimJardiance | $38 | $21,11429 claims |
| AstraZenecaFarxiga | $59 | $7,74913 claims |
| AbbVieSynthroid | $503 | $2,05125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Park River
- Joel JohnsonPark River$5K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.